(Q30311195)

16 June 2017

1 reference

title

Inhibition of aromatase: insights from recent studies (English)

1 reference

16 June 2017

Richard J Santen

1

1 reference

16 June 2017

publication date

1 September 2003

1 reference

16 June 2017

1 reference

16 June 2017

volume

68

1 reference

16 June 2017

issue

7-8

1 reference

16 June 2017

page(s)

559-567

1 reference

Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives

16 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Endocrine treatment of breast cancer in women

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Biomedicine. Defining the "S" in SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

New Perspective on Cancer of the Contralateral Breast: A Marker for Assessing Tamoxifen as a Preventive Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Molecular determinants of the estrogen receptor-coactivator interface

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

New approaches to the understanding of tamoxifen action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Role of aromatase in endometrial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Aromatase and gynecomastia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Use of aromatase inhibitors in precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Tissue-specific synthesis and oxidative metabolism of estrogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Endogenous estrogens as carcinogens through metabolic activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2803%2900096-5

7 January 2021

10.1016/S0039-128X(03)00096-5

Identifiers

DOI

1 reference

16 June 2017

1 reference